TP53 and adenocarcinoma: PIK3CA mutations (57.1% vs 18.2%, p=0.03) were significantly enriched in SCC, whereas alterations of TP53, ARID1B, DICER1, ERBB3, NF1, and TEK were exclusively detected in patients with adenocarcinoma in our cohort.